Advertisement

Digestive Diseases and Sciences

, Volume 53, Issue 6, pp 1716–1720 | Cite as

Silymarin in the Treatment of Patients with Primary Sclerosing Cholangitis: An Open-Label Pilot Study

  • Paul AnguloEmail author
  • Roberta A. Jorgensen
  • Kris V. Kowdley
  • Keith D. Lindor
Original Paper

Abstract

No effective medical therapy is available for patients with primary sclerosing cholangitis (PSC). We evaluated the safety and estimated the efficacy of silymarin in patients with PSC in a pilot study. Thirty patients with PSC were enrolled. Silymarin, 140 mg orally three times daily, was given for 1 year. A statistically significant improvement in serum alkaline phosphatase activity (1131 ± 216 vs. 861 ± 139, P = 0.007), and aspartate aminotransferase (AST) levels (116 ± 15 vs. 83 ± 11, P = 0.01) occurred with treatment. Serum bilirubin levels were not significantly affected by the treatment, while serum albumin and the Mayo risk score remained essentially unchanged. Overall, 34% of patients had a positive response to silymarin as defined by ≥50% improvement or normal status in liver tests. The results of this pilot study warrant further evaluation of silymarin in patients with PSC in a large-scale, controlled trial.

Keywords

Primary sclerosing cholangitis Silymarin Treatment 

Abbreviations

AST

Aspartate aminotransferase

PSC

Primary sclerosing cholangitis

Notes

Acknowledgements

KVK is supported in part by K24 DK02957-01.

References

  1. 1.
    Angulo P, Lindor KD (1999) Primary sclerosing cholangitis. Hepatology 30:325–332PubMedCrossRefGoogle Scholar
  2. 2.
    Lee YM, Kaplan MM (1995) Primary slcerosing cholangitis. N Engl J Med 332:924–933PubMedCrossRefGoogle Scholar
  3. 3.
    Graziadei IW, Wiesner RH, Marotta PJ et al (1999) Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 30:1121–1127PubMedCrossRefGoogle Scholar
  4. 4.
    Muriel P, Garcia-Pina T, Perez-Alvarez V et al (1992) Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J Appl Toxicol 12:439–442PubMedCrossRefGoogle Scholar
  5. 5.
    Ramellini G, Meldolesi J (1974) Stabilization of isolated rat liver plasma membranes by treatment in vitro with silymarin. Arzneim Forsch 24:806–808Google Scholar
  6. 6.
    Dehmlow C, Erhard J, de Groot H (1996) Inhibition of Kupffer cells function as an explanation for the hepatoprotective properties of silibinin. Hepatology 23:749–754PubMedCrossRefGoogle Scholar
  7. 7.
    Leuschner U, Dienes H, Guldutuna S et al (1990) Ursodeoxycholic acid influences immune parameters in patients with primary biliary cirrhosis. Hepatology 12:A957Google Scholar
  8. 8.
    Meroni P, Barcellini W, Borghi M et al (1988) Silybin inhibition of human T-lymphocyte activation. Int J Tissue react 10:177–181PubMedGoogle Scholar
  9. 9.
    Lang I, Nekam K, Deak G et al (1990) Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers. Ital J Gastroenterol 22:283–287PubMedGoogle Scholar
  10. 10.
    Boigk G, Stroedter L, Herbst H et al (1997) Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26:643–649PubMedCrossRefGoogle Scholar
  11. 11.
    Fuchs EC, Gressne AM, Weyhenmayer R et al (1995) Identification of the antifibrogenic properties of silibinin: effect on TGF-b and matrix gene expression of hepatic stellate cells. Hepatology 22:286ACrossRefGoogle Scholar
  12. 12.
    Wenzel S (1996) Effects of silibinin and antioxidants on high glucose induced alterations of fibronectin turnover in human mesangial cell cultures. J Pharmacol Exp Ther 279:1520–1526PubMedGoogle Scholar
  13. 13.
    Salmi H, Sarna S (1982) Effect of silymarin on chemical, functional and morphological alterations of the liver. Scand J Gastroenterol 17:517–520PubMedCrossRefGoogle Scholar
  14. 14.
    Buzzelli G, Moscarella S, Giusti A et al (1993) A pilot study on the liver protective effect of silybin-phopshatidyl complex (IdB1016) in chronic active hepatitis. Int J Clin Pharm Therap Toxicol 31:456–460Google Scholar
  15. 15.
    Ferenci P, Dragosics B, Dittrich H et al (1989) Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 9:105–113PubMedCrossRefGoogle Scholar
  16. 16.
    MacCarty RL, LaRusso NF, Wiesner RH et al (1983) Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology 149:39–44PubMedGoogle Scholar
  17. 17.
    Kim WR, Poterucha JJ, Wiesner RH et al (1999) The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 29:1643–1648PubMedCrossRefGoogle Scholar
  18. 18.
    Angulo P, Lindor KD (2000) Primary sclerosing cholangitis: emerging new promising therapies. J Clin Gastroenterol 31:271–273PubMedCrossRefGoogle Scholar
  19. 19.
    Harnois DM, Angulo P, Jorgensen RA et al (2001) High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 96:1558–1562PubMedCrossRefGoogle Scholar
  20. 20.
    Mitchell SA, Bansi DS, Hunt N et al (2001) A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121:900–907PubMedCrossRefGoogle Scholar
  21. 21.
    Kamath PS, Wiesner RH, Malinchoc M et al (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33:464–470PubMedCrossRefGoogle Scholar
  22. 22.
    Pares A, Planas, Torres M et al (1998) Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 28:615–621 PubMedCrossRefGoogle Scholar
  23. 23.
    Angulo P, Patel T, Jorgensen RA et al (2000) Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 32:897–900PubMedCrossRefGoogle Scholar
  24. 24.
    Schuppan D, Hahn EG (2001) Clinical studies with silymarin: fibrosis progression is the end point. Hepatology 33:483–484PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Paul Angulo
    • 1
    Email author
  • Roberta A. Jorgensen
    • 1
  • Kris V. Kowdley
    • 2
  • Keith D. Lindor
    • 1
  1. 1.Division of Gastroenterology and HepatologyMayo Clinic and FoundationRochesterUSA
  2. 2.Division of Gastroenterology and HepatologyUniversity of Washington School of MedicineSeattleUSA

Personalised recommendations